Cover Image
Market Research Report

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Published by Transparency Market Research Product code 839627
Published Content info 199 Pages
Delivery time: 1-2 business days
Price
Back to Top
Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027
Published: April 10, 2019 Content info: 199 Pages
Description

Title:
Viral Vector and Plasmid DNA Manufacturing Market (Type - Lentivirus, Adenovirus, Adeno-Associated Virus (AAV), Plasmid DNA; Application - Gene Therapy, Vaccinology; Disease - Genetic Disorders, Cancer, Infectious Disease; End user - Biotech Companies, Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027.

Overview

This report analyzes the current and future scenario of the global viral vector & plasmid DNA manufacturing market for the period 2019 to 2027. Increase in prevalence and incidence rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with rare disorders, and raised acceptance for comparatively newer treatment options in developing countries are likely to be major drivers of the global viral vector & plasmid DNA manufacturing market during the forecast period.

The viral vector & plasmid DNA manufacturing market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on type, application, disease, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the viral vector & plasmid DNA manufacturing market.

Key Segments

Based on type, the global viral vector & plasmid DNA manufacturing market has been segmented into lentivirus, adenovirus, adeno-Associated Virus (AAV), plasmid DNA, and others. In terms of application, the global viral vector & plasmid DNA manufacturing market has been divided into gene therapy, vaccinology, and others. Based on disease, the market has been segregated into genetic disorders, cancer, infectious disease, and others. In terms of end-user, the market has been bifurcated into biotech companies and research institutes. The market size and forecast for each of these segments have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year.

Regional Outlook

In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global viral vector & plasmid DNA manufacturing market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza. The global viral vector & plasmid DNA manufacturing market has been segmented as below:

Viral Vector & Plasmid DNA Manufacturing Market, by Type

  • Lentivirus
  • Adenovirus
  • Adeno-Associated Virus (AAV)
  • Plasmid DNA
  • Others

Viral Vector & Plasmid DNA Manufacturing Market, by Application

  • Gene Therapy
  • Vaccinology
  • Others

Viral Vector & Plasmid DNA Manufacturing Market, by Disease

  • Genetic Disorders
  • Cancer
  • Infectious Disease
  • Others

Viral Vector & Plasmid DNA Manufacturing Market , by End-user

  • Biotech Companies
  • Research Institutes

Viral Vector & Plasmid DNA Manufacturing Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa
Table of Contents

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Viral Vector & Plasmid DNA Manufacturing Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Market Outlook

  • 5.1. Top 3 players operating in the market space
  • 5.2. Key Mergers & Acquisitions
  • 5.2. List of Manufacturer by Location of Manufacturing Facility and Type of Vector Production

6. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
    • 6.3.1. Retroviruses
    • 6.3.2. Adenoviruses
    • 6.3.3. Adeno-associated Viruses
    • 6.3.4. Plasmid DNA
    • 6.3.5. Others
  • 6.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type

7. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
    • 7.3.1. Gene Therapy
    • 7.3.2. Vaccinology
    • 7.3.3. Others
  • 7.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application

8. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Disease

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
    • 8.3.1. Genetic Disorders
    • 8.3.2. Cancer
    • 8.3.3. Infectious Disease
    • 8.3.4. Others
  • 8.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease

9. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
    • 9.3.1. Biotech Companies
    • 9.3.2. Research Institutes
  • 9.4. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user

10. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Region

11. North America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
    • 11.2.1. Retroviruses
    • 11.2.2. Adenoviruses
    • 11.2.3. Adeno-associated Viruses
    • 11.2.4. Plasmid DNA
    • 11.2.5. Others
  • 11.3. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
    • 11.3.1. Gene Therapy
    • 11.3.2. Vaccinology
    • 11.3.3. Others
  • 11.4. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
    • 11.4.1. Genetic Disorders
    • 11.4.2. Cancer
    • 11.4.3. Infectious Disease
    • 11.4.4. Others
  • 11.5. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
    • 11.5.1. Biotech Companies
    • 11.5.2. Research Institutes
  • 11.6. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country, 2017-2027
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
    • 11.7.1. by Type
    • 11.7.2. by Application
    • 11.7.3. by Disease
    • 11.7.4. by End-user
    • 11.7.5. by Country

12. Europe Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
    • 12.2.1. Retroviruses
    • 12.2.2. Adenoviruses
    • 12.2.3. Adeno-associated Viruses
    • 12.2.4. Plasmid DNA
    • 12.2.5. Others
  • 12.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
    • 12.3.1. Gene Therapy
    • 12.3.2. Vaccinology
    • 12.3.3. Others
  • 12.4. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
    • 12.4.1. Genetic Disorders
    • 12.4.2. Cancer
    • 12.4.3. Infectious Disease
    • 12.4.4. Others
  • 12.5. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
    • 12.5.1. Biotech Companies
    • 12.5.2. Research Institutes
  • 12.6. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
    • 12.7.1. by Type
    • 12.7.2. by Application
    • 12.7.3. by Disease
    • 12.7.4. by End-user
    • 12.7.5. by Country/Sub-region

13. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
    • 13.2.1. Retroviruses
    • 13.2.2. Adenoviruses
    • 13.2.3. Adeno-associated Viruses
    • 13.2.4. Plasmid DNA
    • 13.2.5. Others
  • 13.3. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
    • 13.3.1. Gene Therapy
    • 13.3.2. Vaccinology
    • 13.3.3. Others
  • 13.4. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
    • 13.4.1. Genetic Disorders
    • 13.4.2. Cancer
    • 13.4.3. Infectious Disease
    • 13.4.4. Others
  • 13.5. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
    • 13.5.1. Biotech Companies
    • 13.5.2. Research Institutes
  • 13.6. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
    • 13.7.1. by Type
    • 13.7.2. by Application
    • 13.7.3. by Disease
    • 13.7.4. by End-user
    • 13.7.5. by Country/Sub-region

14. Latin America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
    • 14.2.1. Retroviruses
    • 14.2.2. Adenoviruses
    • 14.2.3. Adeno-associated Viruses
    • 14.2.4. Plasmid DNA
    • 14.2.5. Others
  • 14.3. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
    • 14.3.1. Gene Therapy
    • 14.3.2. Vaccinology
    • 14.3.3. Others
  • 14.4. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
    • 14.4.1. Genetic Disorders
    • 14.4.2. Cancer
    • 14.4.3. Infectious Disease
    • 14.4.4. Others
  • 14.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
    • 14.5.1. Biotech Companies
    • 14.5.2. Research Institutes
  • 14.6. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
    • 14.7.1. by Type
    • 14.7.2. by Application
    • 14.7.3. by Disease
    • 14.7.4. by End-user
    • 14.7.5. by Country/Sub-region

15. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017-2027
    • 15.2.1. Retroviruses
    • 15.2.2. Adenoviruses
    • 15.2.3. Adeno-associated Viruses
    • 15.2.4. Plasmid DNA
    • 15.2.5. Others
  • 15.3. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017-2027
    • 15.3.1. Gene Therapy
    • 15.3.2. Vaccinology
    • 15.3.3. Others
  • 15.4. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017-2027
    • 15.4.1. Genetic Disorders
    • 15.4.2. Cancer
    • 15.4.3. Infectious Disease
    • 15.4.4. Others
  • 15.5. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017-2027
    • 15.5.1. Biotech Companies
    • 15.5.2. Research Institutes
  • 15.6. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017-2027
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis
    • 15.7.1. by Type
    • 15.7.2. by Application
    • 15.7.3. by Disease
    • 15.7.4. by End-user
    • 15.7.5. by Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by Tier and Size of companies)
  • 16.2. Company Profiles
    • 16.2.1. Lonza
      • 16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.1.2. Product Portfolio
      • 16.2.1.3. SWOT Analysis
      • 16.2.1.4. Financial Overview
      • 16.2.1.5. Strategic Overview
    • 16.2.2. Catapult
      • 16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.2.2. Product Portfolio
      • 16.2.2.3. SWOT Analysis
      • 16.2.2.4. Financial Overview
      • 16.2.2.5. Strategic Overview
    • 16.2.3. uniQure N.V.
      • 16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.3.2. Product Portfolio
      • 16.2.3.3. SWOT Analysis
      • 16.2.3.4. Financial Overview
      • 16.2.3.5. Strategic Overview
    • 16.2.4. FUJIFILM Diosynth Biotechnologies
      • 16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.4.2. Product Portfolio
      • 16.2.4.3. SWOT Analysis
      • 16.2.4.4. Financial Overview
      • 16.2.4.5. Strategic Overview
    • 16.2.5. Kaneka Eurogentec S.A.
      • 16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.5.2. Product Portfolio
      • 16.2.5.3. SWOT Analysis
      • 16.2.5.4. Financial Overview
      • 16.2.5.5. Strategic Overview
    • 16.2.6. Oxford Biomedica
      • 16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.6.2. Product Portfolio
      • 16.2.6.3. SWOT Analysis
      • 16.2.6.4. Financial Overview
      • 16.2.6.5. Strategic Overview
    • 16.2.7. Spark Therapeutics, Inc.
      • 16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.7.2. Product Portfolio
      • 16.2.7.3. SWOT Analysis
      • 16.2.7.4. Financial Overview
      • 16.2.7.5. Strategic Overview
    • 16.2.8. Cobrabiologics
      • 16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.8.2. Product Portfolio
      • 16.2.8.3. SWOT Analysis
      • 16.2.8.4. Financial Overview
      • 16.2.8.5. Strategic Overview
    • 16.2.9. Merck kGA
      • 16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.9.2. Product Portfolio
      • 16.2.9.3. SWOT Analysis
      • 16.2.9.4. Financial Overview
      • 16.2.9.5. Strategic Overview

List of Tables

  • Table 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
  • Table 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
  • Table 03: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
  • Table 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
  • Table 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017?2027
  • Table 06: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017?2027
  • Table 07: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
  • Table 08: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
  • Table 09: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
  • Table 10: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
  • Table 11: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 12: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
  • Table 13: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
  • Table 14: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
  • Table 15: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
  • Table 16: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 17: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
  • Table 18: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
  • Table 19: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
  • Table 20: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
  • Table 21: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 22: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
  • Table 23: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
  • Table 24: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
  • Table 25: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027
  • Table 26: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 27: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027
  • Table 28: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027
  • Table 29: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027
  • Table 30: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

List of Figures

  • Figure 01: Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Viral Vector & Plasmid DNA Manufacturing Market Value, by Type, 2018(A)
  • Figure 03: Viral Vector & Plasmid DNA Manufacturing Market Snapshot
  • Figure 04: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type
  • Figure 05: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application
  • Figure 06: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease
  • Figure 07: Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user
  • Figure 08: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017?2027
  • Figure 09: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type (2018)
  • Figure 10: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user (2018)
  • Figure 11: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region (2018)
  • Figure 12: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2018-2026
  • Figure 13: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
  • Figure 14: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Lentivirus, 2017?2027
  • Figure 15: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adenovirus, 2017?2027
  • Figure 16: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adeno-Associated Virus (AAV), 2017?2027
  • Figure 17: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Plasmid DNA, 2017?2027
  • Figure 18: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027
  • Figure 19: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2018-2026
  • Figure 20: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
  • Figure 21: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gene Therapy, 2017?2027
  • Figure 22: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vaccinology, 2017?2027
  • Figure 23: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027
  • Figure 24: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019-2027
  • Figure 25: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
  • Figure 26: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Genetic Disorders, 2017?2027
  • Figure 27: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cancer, 2017?2027
  • Figure 28: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Infectious Disease, 2017?2027
  • Figure 29: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027
  • Figure 30: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2018-2026
  • Figure 31: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
  • Figure 32: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biotech Companies
  • Figure 33: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Research Institutes
  • Figure 34: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region, for 2018 and 2027
  • Figure 35: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Region, 2018-2026
  • Figure 36: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
  • Figure 37: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country, 2019-2027
  • Figure 38: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country, 2018 and 2027
  • Figure 39: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019-2027
  • Figure 40: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
  • Figure 41: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019-2027
  • Figure 42: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
  • Figure 43: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019-2027
  • Figure 44: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
  • Figure 45: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019-2027
  • Figure 46: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
  • Figure 47: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
  • Figure 48: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share (%), by Country/Sub-region, 2018 and 2027
  • Figure 49: Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 50: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019-2027
  • Figure 51: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
  • Figure 52: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019-2027
  • Figure 53: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
  • Figure 54: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019-2027
  • Figure 55: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
  • Figure 56: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019-2027
  • Figure 57: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
  • Figure 58: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
  • Figure 59: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 60: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, for 2018 and 2027
  • Figure 61: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019-2027
  • Figure 62: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
  • Figure 63: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019-2027
  • Figure 64: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
  • Figure 65: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019-2027
  • Figure 66: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
  • Figure 67: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019-2027
  • Figure 68: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
  • Figure 69: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
  • Figure 70: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019-2027
  • Figure 71: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, 2018 and 2027
  • Figure 72: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019-2027
  • Figure 73: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
  • Figure 74: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019-2027
  • Figure 75: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
  • Figure 76: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019-2027
  • Figure 77: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
  • Figure 78: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019-2027
  • Figure 79: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
  • Figure 80: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027
  • Figure 81: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-Region, 2019-2027
  • Figure 82: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-Region, 2018 and 2027
  • Figure 83: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019-2027
  • Figure 84: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027
  • Figure 85: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019-2027
  • Figure 86: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027
  • Figure 87: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019-2027
  • Figure 88: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027
  • Figure 89: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019-2027
  • Figure 90: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027
Back to Top